Anticorps monoclonaux en oncologie: declencher une reponse immunitaire en plus de la reduction tumorale specifique.

Anne Gaelle Goubet; Lisa Derosa; Aure Ien Marabelle; Laurence Zitvogel

doi:10.1016/s0001-4079(19)30321-8

Anticorps monoclonaux en oncologie: declencher une reponse immunitaire en plus de la reduction tumorale specifique.

Anne Gaelle Goubet, Lisa Derosa, Aure Ien Marabelle, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

The latest discoveries made in fundamental cancer biology and the technical developments have maked best use of monoclonal antibodies in oncology.: These biodrugs have broadened the perspectives of cancer treatment This growing therapeutic part includes monoclonal antibodies against tumor antigens or immunomodulatory molecules and bispecific antibodies. The efficacy of the monoclonal antibodies is related to a tumoral regression and initiation of an adaptative immnune response, Our review resume the most widely used monoclonal antibodies in oncology and take an interest in biotechnology and clinico-biology advances relative to the use of these biotherapies paving the way to new therapeutic views:.

Titre traduit de la contribution	Monoclonal antibodies to treat cancer: initiate an immune response besides a specific tumor regression.
langue originale	Français
Pages (de - à)	707-735
Nombre de pages	29
journal	Bulletin de l'Academie Nationale de Medecine
Volume	202
Numéro de publication	3-4
Les DOIs	https://doi.org/10.1016/s0001-4079(19)30321-8
état	Publié - 1 mars 2018
Modification externe	Oui

mots-clés

Anti-tumor immunity
Cancer
Immunomo- dulation
Immunotherapies
Monoclonal antibodies

Accès au document

10.1016/s0001-4079(19)30321-8

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{4b63359269ac429886a7b5c6ab28bad3,

title = "Anticorps monoclonaux en oncologie: declencher une reponse immunitaire en plus de la reduction tumorale specifique.",

abstract = "The latest discoveries made in fundamental cancer biology and the technical developments have maked best use of monoclonal antibodies in oncology.: These biodrugs have broadened the perspectives of cancer treatment This growing therapeutic part includes monoclonal antibodies against tumor antigens or immunomodulatory molecules and bispecific antibodies. The efficacy of the monoclonal antibodies is related to a tumoral regression and initiation of an adaptative immnune response, Our review resume the most widely used monoclonal antibodies in oncology and take an interest in biotechnology and clinico-biology advances relative to the use of these biotherapies paving the way to new therapeutic views:.",

keywords = "Anti-tumor immunity, Cancer, Immunomo- dulation, Immunotherapies, Monoclonal antibodies",

author = "Goubet, {Anne Gaelle} and Lisa Derosa and Marabelle, {Aure Ien} and Laurence Zitvogel",

year = "2018",

month = mar,

day = "1",

doi = "10.1016/s0001-4079(19)30321-8",

language = "Fran{\c c}ais",

volume = "202",

pages = "707--735",

journal = "Bulletin de l'Academie Nationale de Medecine",

issn = "0001-4079",

number = "3-4",

}

TY - JOUR

T1 - Anticorps monoclonaux en oncologie

T2 - declencher une reponse immunitaire en plus de la reduction tumorale specifique.

AU - Goubet, Anne Gaelle

AU - Derosa, Lisa

AU - Marabelle, Aure Ien

AU - Zitvogel, Laurence

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The latest discoveries made in fundamental cancer biology and the technical developments have maked best use of monoclonal antibodies in oncology.: These biodrugs have broadened the perspectives of cancer treatment This growing therapeutic part includes monoclonal antibodies against tumor antigens or immunomodulatory molecules and bispecific antibodies. The efficacy of the monoclonal antibodies is related to a tumoral regression and initiation of an adaptative immnune response, Our review resume the most widely used monoclonal antibodies in oncology and take an interest in biotechnology and clinico-biology advances relative to the use of these biotherapies paving the way to new therapeutic views:.

AB - The latest discoveries made in fundamental cancer biology and the technical developments have maked best use of monoclonal antibodies in oncology.: These biodrugs have broadened the perspectives of cancer treatment This growing therapeutic part includes monoclonal antibodies against tumor antigens or immunomodulatory molecules and bispecific antibodies. The efficacy of the monoclonal antibodies is related to a tumoral regression and initiation of an adaptative immnune response, Our review resume the most widely used monoclonal antibodies in oncology and take an interest in biotechnology and clinico-biology advances relative to the use of these biotherapies paving the way to new therapeutic views:.

KW - Anti-tumor immunity

KW - Cancer

KW - Immunomo- dulation

KW - Immunotherapies

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=85057624182&partnerID=8YFLogxK

U2 - 10.1016/s0001-4079(19)30321-8

DO - 10.1016/s0001-4079(19)30321-8

M3 - Article

AN - SCOPUS:85057624182

SN - 0001-4079

VL - 202

SP - 707

EP - 735

JO - Bulletin de l'Academie Nationale de Medecine

JF - Bulletin de l'Academie Nationale de Medecine

IS - 3-4

ER -